

Defining Survival as an Outcome Measure in Amyotrophic Lateral Sclerosis

Paul H. Gordon, MD; Philippe Corcia, MD, PhD; Lucette Lacomblez, MD; Ksenia Pochigaeva, MD; Jean-Louis Abitbol, MD; Merit Cudkowicz, MD; P. Nigel Leigh, FMedSci; Vincent Meininger, MD, PhD

Arch Neurol. 2009;66(6):758-761

eTable. Entry Criteria and Baseline Data

	Xaliproden Trial 1	Xaliproden Trial 2	Pentoxifylline Trial
Admission criteria			
Age range, y	18-75	18-75	18-80
VC, % of predicted value	≥60	≥60	<100
Baseline data^a			
No. of participants enrolled	867	1210	400
Age, y	55.8 (11.6)	55.8 (11)	56.9 (11.9)
VC, % of predicted value	88.0 (16.3)	86.9 (16.6)	70.9 (20.9)
Disease duration, mo	19.6 (12.9)	25.2 (14.3)	24.6 (11.8)

Abbreviation: VC, vital capacity.

^aUnless otherwise indicated, data are expressed as mean (SD).